SOX2 and esophageal cancer: Furthermore, we found that enhanced SOX2 expression in Eca109 cells promoted chemoresistance to cisplatin, one of the most frequently used chemotherapeutic drug for esophageal cancer, as demonstrated by a shift in the IC50 (Figure 5C).